Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.38 |
| ▸ | KAT7 | O95251 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4845414 | 0.90 | NR1H2 (0.42) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL24449532 | 0.88 | NR1H2 (0.41) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1184434 | 0.86 | NR1H2 (0.51) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL24449830 | 0.86 | PARP1 (0.50) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL780271 | 0.86 | NR1H2 (0.51) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL18850 | 0.86 | NR1H2 (0.51) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL18342442 | 0.85 | NR1H2 (0.43) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL18342443 | 0.85 | NR1H2 (0.43) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL17068111 | 0.85 | NR1H2 (0.43) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL6231381 | 0.84 | NR1H2 (0.42) | NR1H2MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | NR1H2 633/4885MEN1 1860/4885ALDH1A1 2786/4885 |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | NR1H2 633/4885MEN1 1860/4885ALDH1A1 2786/4885 |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | EP300, KAT2A, KAT6A | NR1H2 633/4885MEN1 1860/4885ALDH1A1 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.